{"id":1311,"date":"2022-08-27T11:17:06","date_gmt":"2022-08-27T18:17:06","guid":{"rendered":"https:\/\/blog.medcram.com\/?p=1311"},"modified":"2022-09-01T11:30:32","modified_gmt":"2022-09-01T18:30:32","slug":"new-study-evaluates-high-dose-ivermectin-fluvoxamine-and-metformin-for-outpatient-covid-19","status":"publish","type":"post","link":"https:\/\/blog.medcram.com\/covid-19\/new-study-evaluates-high-dose-ivermectin-fluvoxamine-and-metformin-for-outpatient-covid-19\/","title":{"rendered":"New Study Evaluates High Dose Ivermectin, Fluvoxamine, and Metformin for Outpatient COVID-19"},"content":{"rendered":"<p style=\"text-align: center;\"><iframe loading=\"lazy\" title=\"YouTube video player\" src=\"https:\/\/www.youtube.com\/embed\/5SeF67AaK74\" width=\"560\" height=\"315\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"><\/iframe><\/p>\n<p><span style=\"font-weight: 400;\">In this video, Dr. Seheult of MedCram discusses a <\/span><a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2201662\"><span style=\"font-weight: 400;\">study<\/span><\/a><span style=\"font-weight: 400;\"> in the NEJM that compares ivermectin, fluvoxamine and metformin in outpatient COVID-19 treatment. This was a phase 3, randomized controlled study. The study looked at how these drugs could prevent hypoxemia, ER visits and hospitalization. This study was funded by the <\/span><a href=\"https:\/\/www.parsemus.org\/\"><span style=\"font-weight: 400;\">Parsemus Foundation<\/span><\/a><span style=\"font-weight: 400;\">. <\/span><\/p>\n<h2>Study participants<\/h2>\n<p><span style=\"font-weight: 400;\">This study was primarily done in the United States with an entrance requirement of 30-85 years of age, overweight or obese category, diagnosed with COVID-19 within the last 3 days, and no more than 7 days of any symptoms. The study took place between 12\/30\/20 to 1\/28\/22 so it contained the different variant waves of alpha, delta and omicron. It recruited a total of 1431 patients and was powered to detect a 30-40% relative risk reduction in hospitalization, ER visits, and low oxygen saturation which was defined as less than 93%. The study then divided the remaining 1323 patients into different groups that received either metformin up to 1500 mg\/day x 14 days, ivermectin dosed at 390-470 mcg\/kg per day x 3 days, or fluvoxamine at 50 mg twice a day x 14 days. The participants were specifically randomized\u00a0 into 6 groups which included both drugs placebo, one placebo and one ivermectin, one placebo and one fluvoxamine, one placebo and metformin, metformin and ivermectin, metformin and fluvoxamine. <\/span><\/p>\n<h2><span style=\"font-weight: 400;\">Results<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">The results of this study showed that none of the medications reached statistical significance in the primary composite endpoint. However, when looking at the end point for ER visits, hospitalization and\/or death, metformin did reach statistical significance and did at least appear to be improve outcomes in obese\/overweight patients.\u00a0 The overall conclusion was that metformin, ivermectin and fluvoxamine did not prevent severe COVID-19 outcomes in non-hospitalized patients with obesity or in the overweight category.\u00a0<\/span><\/p>\n<h2>Limitations to the study<\/h2>\n<p><span style=\"font-weight: 400;\">Limitations to this study, per the article, included it being limited to only patients between the age of 30 and 85 and to those who were overweight or obese in the United States. These findings may not be able to be generalizable to people outside of these parameters. There was also a smaller percentage of persons who identified themselves as Black or Latinx included in this study.\u00a0 Another limitation the authors acknowledged was that the hypoxemia component was subject to a bias as it was self reported and accuracy of the oximetry monitors at home could not be validated especially with nonprescription brands.\u00a0 Another bias was a recall bias as an emergency department visit or hospitalization could be influenced by a patient\u2019s willingness to seek care. The most accurate and well documented end point however was hospitalization as objective criteria are needed for an admission.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">This study did show some potential promise in using metformin in certain patients but future studies are needed to further elucidate that.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">LINKS \/ REFERENCES:<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19 (NEJM) |<\/span><a href=\"https:\/\/www.youtube.com\/redirect?event=video_description&amp;redir_token=QUFFLUhqa0JrTUVmWXJmdXFGb0ZxR2FtUTFjWE5QUXp3Z3xBQ3Jtc0trQXhlZTAtekJqaWxSa2oyc0gtUkFlTENxSGhqZ2EyNDJBdU9ZdEMyOTNFNVhHX1ZNWlFLNktGSEx3YVJvdFRDX1kyN3R5cXJpS0w2NG12Nm95c0dEbHI4VE5WTTlzLVJndEdZdkJCQk5BUEo5VjZTSQ&amp;q=https%3A%2F%2Fwww.nejm.org%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2201662&amp;v=5SeF67AaK74\"> <span style=\"font-weight: 400;\">https:\/\/www.nejm.org\/doi\/full\/10.1056&#8230;<\/span><\/a><\/p>\n<p><span style=\"font-weight: 400;\">Mission (Parsemus Foundation) |<\/span><a href=\"https:\/\/www.youtube.com\/redirect?event=video_description&amp;redir_token=QUFFLUhqbXBGRjBGcHVRT29EMHpNNXdLNmZVLVpGVGVMQXxBQ3Jtc0tuN1ljY3lxNWhQYVRXZW1BZ2NtU2VkeFJ6WU1lNWwweTl3c2lsZVNmTzRaZkRhRElKTmtKaUo3a3VzZktpaFlEY3doa2pTVWtfRkVfaTBOa2huclVtRHJTQnBFMm9oTGRJcEN5RnU2Y2pZcXVnaXU4bw&amp;q=https%3A%2F%2Fwww.parsemus.org%2F&amp;v=5SeF67AaK74\"> <span style=\"font-weight: 400;\">https:\/\/www.parsemus.org<\/span><\/a><\/p>\n<p><span style=\"font-weight: 400;\">Prevention Protocol (FLCCC) |<\/span><a href=\"https:\/\/www.youtube.com\/redirect?event=video_description&amp;redir_token=QUFFLUhqbEYxX2hya3FqM2twV0JzNDdHbjFqRWYzZ2FjQXxBQ3Jtc0trT2h4dnpMbE1ZMjNOSGpGbDBlZ0tGVTVyU2FYeG1Cc1hUMVVrRk9lU0tfVXdwVmJsWjljQ3FaY3hEYXZoZDBCcmJmV3RLVUthTHFYSXVmak5RWndxRkk3bmNUSnk2a2dHNThxRHZEc2hWNlh4NU5mMA&amp;q=https%3A%2F%2Fcovid19criticalcare.com%2Fwp-content%2Fuploads%2F2020%2F11%2FFLCCC-Alliance-I-MASKplus-Protocol-ENGLISH.pdf&amp;v=5SeF67AaK74\"> <span style=\"font-weight: 400;\">https:\/\/covid19criticalcare.com\/wp-co&#8230;<\/span><\/a><\/p>\n<p><span style=\"font-weight: 400;\">All coronavirus updates are at MedCram.com (including more discussion on delta variant covid, COVID Delta, COVID children, natural immunity COVID 19, and more).<\/span><\/p>\n<p><span style=\"font-weight: 400;\">MedCram Update 46:<\/span><a href=\"https:\/\/www.youtube.com\/watch?v=EFRwnhfWXxo&amp;t=0s\"> <span style=\"font-weight: 400;\">https:\/\/youtu.be\/EFRwnhfWXxo<\/span><\/a><\/p>\n<p><span style=\"font-weight: 400;\">MedCram Update 47:<\/span><a href=\"https:\/\/www.youtube.com\/watch?v=H1LHgyfPPQ8&amp;t=0s\"> <span style=\"font-weight: 400;\">https:\/\/youtu.be\/H1LHgyfPPQ8<\/span><\/a><\/p>\n<p><span style=\"font-weight: 400;\">MedCram Update 132:<\/span><a href=\"https:\/\/www.youtube.com\/watch?v=9OZZ6_M4OB0&amp;t=0s\"> <span style=\"font-weight: 400;\">https:\/\/youtu.be\/9OZZ6_M4OB0<\/span><\/a><\/p>\n<h2><b>Stay Tuned for More Updates\u00a0<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">Our COVID-19 videos are always available for <\/span><i><span style=\"font-weight: 400;\">free <\/span><\/i><span style=\"font-weight: 400;\">(and ad-free) at<\/span><a href=\"https:\/\/www.medcram.com\/collections?category=covid-19-SARS-CoV-2\"> <span style=\"font-weight: 400;\">MedCram.com<\/span><\/a><span style=\"font-weight: 400;\">. In addition, check out our full library of courses and lectures on subjects ranging from<\/span> <a href=\"https:\/\/www.medcram.com\/courses\/hypertension-explained-clearly-2\"><span style=\"font-weight: 400;\">Hypertension Explained Clearly<\/span><\/a><span style=\"font-weight: 400;\"> to<\/span><a href=\"https:\/\/www.medcram.com\/courses\/sleep-apnea-explained-clearly\"> <span style=\"font-weight: 400;\">Sleep Apnea Explained Clearly<\/span><\/a><span style=\"font-weight: 400;\"> course and many more!<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Meanwhile, you can find all of our COVID-19 videos compiled <\/span><a href=\"https:\/\/www.medcram.com\/collections?category=covid-19-SARS-CoV-2\"><span style=\"font-weight: 400;\">here<\/span><\/a><span style=\"font-weight: 400;\">.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Visit <\/span><a href=\"https:\/\/www.medcram.com\/\"><span style=\"font-weight: 400;\">MedCram.com<\/span><\/a><span style=\"font-weight: 400;\"> for updates on Monkeypox virus infectious disease and more.<\/span><\/p>\n<!-- AddThis Advanced Settings generic via filter on the_content --><!-- AddThis Share Buttons generic via filter on the_content -->","protected":false},"excerpt":{"rendered":"<p>In this video, Dr. Seheult of MedCram discusses a study in the NEJM that compares ivermectin, fluvoxamine and metformin in outpatient COVID-19 treatment. This was a phase 3, randomized controlled study. The study looked at how these drugs could prevent hypoxemia, ER visits and hospitalization. This study was funded by the Parsemus Foundation. Study participants&hellip;<!-- AddThis Advanced Settings generic via filter on get_the_excerpt --><!-- AddThis Share Buttons generic via filter on get_the_excerpt --><\/p>\n","protected":false},"author":8,"featured_media":1312,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[25,16],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>New Study Evaluates High Dose Ivermectin, Fluvoxamine, and Metformin for Outpatient COVID-19 - Medcram Blog<\/title>\n<meta name=\"description\" content=\"In this video, Dr. Seheult of MedCram discusses a study in the NEJM that compares ivermectin, fluvoxamine and metformin in outpatient COVID-19 treatment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blog.medcram.com\/covid-19\/new-study-evaluates-high-dose-ivermectin-fluvoxamine-and-metformin-for-outpatient-covid-19\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New Study Evaluates High Dose Ivermectin, Fluvoxamine, and Metformin for Outpatient COVID-19 - Medcram Blog\" \/>\n<meta property=\"og:description\" content=\"In this video, Dr. Seheult of MedCram discusses a study in the NEJM that compares ivermectin, fluvoxamine and metformin in outpatient COVID-19 treatment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blog.medcram.com\/covid-19\/new-study-evaluates-high-dose-ivermectin-fluvoxamine-and-metformin-for-outpatient-covid-19\/\" \/>\n<meta property=\"og:site_name\" content=\"Medcram Blog\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/MedCram\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-27T18:17:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-09-01T18:30:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/blog.medcram.com\/wp-content\/uploads\/2022\/09\/ivermectin-fluvox-metformin.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Betty Seheult\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@medcramvideos\" \/>\n<meta name=\"twitter:site\" content=\"@medcramvideos\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Betty Seheult\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/blog.medcram.com\/covid-19\/new-study-evaluates-high-dose-ivermectin-fluvoxamine-and-metformin-for-outpatient-covid-19\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/blog.medcram.com\/covid-19\/new-study-evaluates-high-dose-ivermectin-fluvoxamine-and-metformin-for-outpatient-covid-19\/\"},\"author\":{\"name\":\"Betty Seheult\",\"@id\":\"https:\/\/blog.medcram.com\/#\/schema\/person\/0f1abd9ef5d4bf6b5fe0b0d50b9fd9c2\"},\"headline\":\"New Study Evaluates High Dose Ivermectin, Fluvoxamine, and Metformin for Outpatient COVID-19\",\"datePublished\":\"2022-08-27T18:17:06+00:00\",\"dateModified\":\"2022-09-01T18:30:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/blog.medcram.com\/covid-19\/new-study-evaluates-high-dose-ivermectin-fluvoxamine-and-metformin-for-outpatient-covid-19\/\"},\"wordCount\":614,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/blog.medcram.com\/#organization\"},\"articleSection\":[\"COVID-19\",\"Infectious Disease\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/blog.medcram.com\/covid-19\/new-study-evaluates-high-dose-ivermectin-fluvoxamine-and-metformin-for-outpatient-covid-19\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/blog.medcram.com\/covid-19\/new-study-evaluates-high-dose-ivermectin-fluvoxamine-and-metformin-for-outpatient-covid-19\/\",\"url\":\"https:\/\/blog.medcram.com\/covid-19\/new-study-evaluates-high-dose-ivermectin-fluvoxamine-and-metformin-for-outpatient-covid-19\/\",\"name\":\"New Study Evaluates High Dose Ivermectin, Fluvoxamine, and Metformin for Outpatient COVID-19 - Medcram Blog\",\"isPartOf\":{\"@id\":\"https:\/\/blog.medcram.com\/#website\"},\"datePublished\":\"2022-08-27T18:17:06+00:00\",\"dateModified\":\"2022-09-01T18:30:32+00:00\",\"description\":\"In this video, Dr. Seheult of MedCram discusses a study in the NEJM that compares ivermectin, fluvoxamine and metformin in outpatient COVID-19 treatment.\",\"breadcrumb\":{\"@id\":\"https:\/\/blog.medcram.com\/covid-19\/new-study-evaluates-high-dose-ivermectin-fluvoxamine-and-metformin-for-outpatient-covid-19\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/blog.medcram.com\/covid-19\/new-study-evaluates-high-dose-ivermectin-fluvoxamine-and-metformin-for-outpatient-covid-19\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/blog.medcram.com\/covid-19\/new-study-evaluates-high-dose-ivermectin-fluvoxamine-and-metformin-for-outpatient-covid-19\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/blog.medcram.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"COVID-19\",\"item\":\"https:\/\/blog.medcram.com\/category\/covid-19\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"New Study Evaluates High Dose Ivermectin, Fluvoxamine, and Metformin for Outpatient COVID-19\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/blog.medcram.com\/#website\",\"url\":\"https:\/\/blog.medcram.com\/\",\"name\":\"Medcram Blog\",\"description\":\"Medcram Blog\",\"publisher\":{\"@id\":\"https:\/\/blog.medcram.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/blog.medcram.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/blog.medcram.com\/#organization\",\"name\":\"MedCram\",\"url\":\"https:\/\/blog.medcram.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/blog.medcram.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/blog.medcram.com\/wp-content\/uploads\/2017\/05\/logo.png\",\"contentUrl\":\"https:\/\/blog.medcram.com\/wp-content\/uploads\/2017\/05\/logo.png\",\"width\":152,\"height\":89,\"caption\":\"MedCram\"},\"image\":{\"@id\":\"https:\/\/blog.medcram.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/MedCram\/\",\"https:\/\/twitter.com\/medcramvideos\",\"https:\/\/www.instagram.com\/medcram\/\",\"https:\/\/www.youtube.com\/c\/medcram\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/blog.medcram.com\/#\/schema\/person\/0f1abd9ef5d4bf6b5fe0b0d50b9fd9c2\",\"name\":\"Betty Seheult\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/blog.medcram.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/2ed8bbd19f04d10eaff8a77705d7f213?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/2ed8bbd19f04d10eaff8a77705d7f213?s=96&d=mm&r=g\",\"caption\":\"Betty Seheult\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"New Study Evaluates High Dose Ivermectin, Fluvoxamine, and Metformin for Outpatient COVID-19 - Medcram Blog","description":"In this video, Dr. Seheult of MedCram discusses a study in the NEJM that compares ivermectin, fluvoxamine and metformin in outpatient COVID-19 treatment.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blog.medcram.com\/covid-19\/new-study-evaluates-high-dose-ivermectin-fluvoxamine-and-metformin-for-outpatient-covid-19\/","og_locale":"en_US","og_type":"article","og_title":"New Study Evaluates High Dose Ivermectin, Fluvoxamine, and Metformin for Outpatient COVID-19 - Medcram Blog","og_description":"In this video, Dr. Seheult of MedCram discusses a study in the NEJM that compares ivermectin, fluvoxamine and metformin in outpatient COVID-19 treatment.","og_url":"https:\/\/blog.medcram.com\/covid-19\/new-study-evaluates-high-dose-ivermectin-fluvoxamine-and-metformin-for-outpatient-covid-19\/","og_site_name":"Medcram Blog","article_publisher":"https:\/\/www.facebook.com\/MedCram\/","article_published_time":"2022-08-27T18:17:06+00:00","article_modified_time":"2022-09-01T18:30:32+00:00","og_image":[{"width":1280,"height":720,"url":"https:\/\/blog.medcram.com\/wp-content\/uploads\/2022\/09\/ivermectin-fluvox-metformin.jpg","type":"image\/jpeg"}],"author":"Betty Seheult","twitter_card":"summary_large_image","twitter_creator":"@medcramvideos","twitter_site":"@medcramvideos","twitter_misc":{"Written by":"Betty Seheult","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blog.medcram.com\/covid-19\/new-study-evaluates-high-dose-ivermectin-fluvoxamine-and-metformin-for-outpatient-covid-19\/#article","isPartOf":{"@id":"https:\/\/blog.medcram.com\/covid-19\/new-study-evaluates-high-dose-ivermectin-fluvoxamine-and-metformin-for-outpatient-covid-19\/"},"author":{"name":"Betty Seheult","@id":"https:\/\/blog.medcram.com\/#\/schema\/person\/0f1abd9ef5d4bf6b5fe0b0d50b9fd9c2"},"headline":"New Study Evaluates High Dose Ivermectin, Fluvoxamine, and Metformin for Outpatient COVID-19","datePublished":"2022-08-27T18:17:06+00:00","dateModified":"2022-09-01T18:30:32+00:00","mainEntityOfPage":{"@id":"https:\/\/blog.medcram.com\/covid-19\/new-study-evaluates-high-dose-ivermectin-fluvoxamine-and-metformin-for-outpatient-covid-19\/"},"wordCount":614,"commentCount":0,"publisher":{"@id":"https:\/\/blog.medcram.com\/#organization"},"articleSection":["COVID-19","Infectious Disease"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blog.medcram.com\/covid-19\/new-study-evaluates-high-dose-ivermectin-fluvoxamine-and-metformin-for-outpatient-covid-19\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blog.medcram.com\/covid-19\/new-study-evaluates-high-dose-ivermectin-fluvoxamine-and-metformin-for-outpatient-covid-19\/","url":"https:\/\/blog.medcram.com\/covid-19\/new-study-evaluates-high-dose-ivermectin-fluvoxamine-and-metformin-for-outpatient-covid-19\/","name":"New Study Evaluates High Dose Ivermectin, Fluvoxamine, and Metformin for Outpatient COVID-19 - Medcram Blog","isPartOf":{"@id":"https:\/\/blog.medcram.com\/#website"},"datePublished":"2022-08-27T18:17:06+00:00","dateModified":"2022-09-01T18:30:32+00:00","description":"In this video, Dr. Seheult of MedCram discusses a study in the NEJM that compares ivermectin, fluvoxamine and metformin in outpatient COVID-19 treatment.","breadcrumb":{"@id":"https:\/\/blog.medcram.com\/covid-19\/new-study-evaluates-high-dose-ivermectin-fluvoxamine-and-metformin-for-outpatient-covid-19\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blog.medcram.com\/covid-19\/new-study-evaluates-high-dose-ivermectin-fluvoxamine-and-metformin-for-outpatient-covid-19\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/blog.medcram.com\/covid-19\/new-study-evaluates-high-dose-ivermectin-fluvoxamine-and-metformin-for-outpatient-covid-19\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blog.medcram.com\/"},{"@type":"ListItem","position":2,"name":"COVID-19","item":"https:\/\/blog.medcram.com\/category\/covid-19\/"},{"@type":"ListItem","position":3,"name":"New Study Evaluates High Dose Ivermectin, Fluvoxamine, and Metformin for Outpatient COVID-19"}]},{"@type":"WebSite","@id":"https:\/\/blog.medcram.com\/#website","url":"https:\/\/blog.medcram.com\/","name":"Medcram Blog","description":"Medcram Blog","publisher":{"@id":"https:\/\/blog.medcram.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blog.medcram.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/blog.medcram.com\/#organization","name":"MedCram","url":"https:\/\/blog.medcram.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blog.medcram.com\/#\/schema\/logo\/image\/","url":"https:\/\/blog.medcram.com\/wp-content\/uploads\/2017\/05\/logo.png","contentUrl":"https:\/\/blog.medcram.com\/wp-content\/uploads\/2017\/05\/logo.png","width":152,"height":89,"caption":"MedCram"},"image":{"@id":"https:\/\/blog.medcram.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/MedCram\/","https:\/\/twitter.com\/medcramvideos","https:\/\/www.instagram.com\/medcram\/","https:\/\/www.youtube.com\/c\/medcram"]},{"@type":"Person","@id":"https:\/\/blog.medcram.com\/#\/schema\/person\/0f1abd9ef5d4bf6b5fe0b0d50b9fd9c2","name":"Betty Seheult","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blog.medcram.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/2ed8bbd19f04d10eaff8a77705d7f213?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2ed8bbd19f04d10eaff8a77705d7f213?s=96&d=mm&r=g","caption":"Betty Seheult"}}]}},"_links":{"self":[{"href":"https:\/\/blog.medcram.com\/wp-json\/wp\/v2\/posts\/1311"}],"collection":[{"href":"https:\/\/blog.medcram.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blog.medcram.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blog.medcram.com\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/blog.medcram.com\/wp-json\/wp\/v2\/comments?post=1311"}],"version-history":[{"count":2,"href":"https:\/\/blog.medcram.com\/wp-json\/wp\/v2\/posts\/1311\/revisions"}],"predecessor-version":[{"id":1314,"href":"https:\/\/blog.medcram.com\/wp-json\/wp\/v2\/posts\/1311\/revisions\/1314"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/blog.medcram.com\/wp-json\/wp\/v2\/media\/1312"}],"wp:attachment":[{"href":"https:\/\/blog.medcram.com\/wp-json\/wp\/v2\/media?parent=1311"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blog.medcram.com\/wp-json\/wp\/v2\/categories?post=1311"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blog.medcram.com\/wp-json\/wp\/v2\/tags?post=1311"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}